Extended Data Fig. 7: Neutralizing activity of monoclonal antibodies in clinical development against SARS-CoV-2 variants.
From: mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
Results of a SARS-CoV-2 pseudovirus neutralization assay. IC50 values for six different monoclonal antibodies, alone or in their clinically designated combinations, for neutralization of wild-type and the indicated mutant SARS-CoV-2 pseudotyped viruses. Antibodies with IC50 values above 1,000 ng ml−1 are plotted as 1,000 ng ml−1. Data are the mean of two independent experiments. Colour gradient indicates IC50 values, ranging from 0 (white) to 1,000 ng ml−1 (red). The combination of REGN10987 and REGN10933 (casirivimab and imdevimab, respectively)14,65,66 has been granted emergency use authorization by the US Food and Drug Administration; the combination of COV2-2196 and COV2-2130 (licensed to AstraZeneca as AZD7442)27 and the combination of C135 and C144 (Rockefeller University)6 are currently in clinical trials (NCT04507256 and NCT04700163, respectively).
